Efficacy and Safety of Levetiracetam for Outpatient Alcohol Detoxification

Abstract

Introduction: Anticonvulsant drugs are increasingly being used for alcohol detoxification in in- and outpatient settings. The aim of this study was to examine the efficacy, medical safety and mid-term outcome of levetiracetam, a drug with no marked liver toxicity, for outpatient alcohol detoxification.

Methods: This was an open-label observational study. After screening eligibility for outpatient alcohol detoxification, patients were seen daily for 5 days and received levetiracetam in a flexible dosage regime between 500 and 4 000 mg/d for a maximum of 7 days. Diazepam was used as a rescue medication. The severity of alcohol withdrawal was evaluated daily using the Alcohol Withdrawal Syndrome Scale (AWSS). Mid-term treatment outcome was assessed at a 6-month follow-up.

Results: A total number of 131 consecutively admitted alcohol-dependent patients received an outpatient detoxification treatment, 122 (93.1%) completed the programme successfully. The mean initial dose of levetiracetam was 1 850 mg/d. Alcohol withdrawal syndrome as indicated by the AWSS score decreased clearly over 5 days. Overall, the medication was well tolerated. There was no treatment discontinuations due to side effects of levetiracetam. No serious medical complications, especially seizures or deliria, were observed during the detoxification. At the 6-month follow-up, 57 patients (43.5%) were still abstinent. Patients with previous detoxifications had a significant higher risk for relapse (HR=1.88; p=0.016; CI 95%: 1.12–3.14) than patients without previous treatments.

Discussion: The findings of this study provide some evidence that levetiracetam is an efficacious and safe treatment option for outpatient alcohol detoxification. Further randomised, controlled trials including mid- and long-term follow-ups are needed to confirm these findings.

References

• 1 American Psychiatric Association .Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) 4th ed.. American Psychiatric Association, Washington, DC; 1994
• 2 Bennett B, Lamberty Y, Bizot JC. et al . Levetiracetam prevents signs of alcohol withdrawal in mice New Research Program and Abstracts of the 156th Annual Meeting of the American Psychiatric Association; May 21, 2003; San Francisco (Abstract NR689).  2003;  58
• 3 Bottlender M, Soyka M. Efficacy of an intensive outpatient rehabilitation program in alcoholism: predictors of outcome 6 months after treatment.  Eur Addict Res. 2005;  11 132-137
• 4 Bottlender M, Soyka M. Outpatient alcoholism treatment: predictors of outcome after 3 years.  Drug Alcohol Depend. 2005;  80 83-89
• 5 Burtscheidt W, Schwarz R, Wolwer W. et al . [Outpatient behavioural treatment in alcoholism: alcohol consumption and sociodemographic factors].  Fortschr Neurol Psychiatr. 2001;  69 526-531
• 6 Chabolla DR, Harnois DM, Meschia JF. Levetiracetam monotherapy for liver transplant patients with seizures.  Transplant Proc. 2003;  35 1480-1481
• 7 Collins MN, Burns T, van den Berk PA. et al . A structured programme for out-patient alcohol detoxification.  Br J Psychiatry. 1990;  156 871-874
• 8 Cramer JA, De Rue K, Devinsky O. et al . A systematic review of the behavioral effects of levetiracetam in adults with epilepsy, cognitive disorders, or an anxiety disorder during clinical trials.  Epilepsy Behav. 2003;  4 124-132
• 9 De Witte P, Pinto E, Ansseau M. et al . Alcohol and withdrawal: from animal research to clinical issues.  Neurosci Biobehav Rev. 2003;  27 189-197
• 10 Franz M, Dlabal H, Kunz S. et al . Treatment of alcohol withdrawal: tiapride and carbamazepine versus clomethiazole.  A pilot study. Eur Arch Psychiatry Clin Neurosci. 2001;  251 185-192
• 11 Fuks B, Gillard M, Michel P. et al . Localization and photoaffinity labelling of the levetiracetam binding site in rat brain and certain cell lines.  Eur J Pharmacol. 2003;  478 11-19
• 12 Gillard M, Chatelain P, Fuks B. Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein.  Eur J Pharmacol. 2006;  536 102-108
• 13 Gower AJ, Noyer M, Verloes R. et al . ucb L059, a novel anti-convulsant drug: pharmacological profile in animals.  Eur J Pharmacol. 1992;  222 193-203
• 14 Heinz A, Dufeu P, Kuhn S. et al . Psychopathological and behavioral correlates of dopaminergic sensitivity in alcohol-dependent patients.  Arch Gen Psychiatry. 1996;  53 1123-1128
• 15 Klijnsma MP, Cameron ML, Burns TP. et al . Out-patient alcohol detoxification − outcome after 2 months.  Alcohol Alcohol. 1995;  30 669-673
• 16 Kosten TR, O’Connor PG. Management of drug and alcohol withdrawal.  N Engl J Med. 2003;  348 1786-1795
• 17 Krebs M, Leopold K, Richter C. et al . Levetiracetam for the treatment of alcohol withdrawal syndrome: an open-label pilot trial.  J Clin Psychopharmacol. 2006;  26 347-349
• 18 LaRoche SM, Helmers SL. The new antiepileptic drugs: scientific review.  JAMA. 2004;  291 605-614
• 19 Loscher W, Honack D, Rundfeldt C. Antiepileptogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy.  J Pharmacol Exp Ther. 1998;  284 474-479
• 20 Lucht M, Kuehn KU, Armbruster J. et al . Alcohol withdrawal treatment in intoxicated vs non-intoxicated patients: a controlled open-label study with tiapride/carbamazepine, clomethiazole and diazepam.  Alcohol Alcohol. 2003;  38 168-175
• 21 Lynch BA, Lambeng N, Nocka K. et al . The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam.  Proc Natl Acad Sci U S A. 2004;  101 9861-9866
• 22 Malcolm R, Myrick H, Brady KT. et al . Update on anticonvulsants for the treatment of alcohol withdrawal.  Am J Addict. 2001;  10 ((Suppl)) 16-23
• 23 Margineanu DG, Klitgaard H. Levetiracetam has no significant gamma-aminobutyric acid-related effect on paired-pulse interaction in the dentate gyrus of rats.  Eur J Pharmacol. 2003;  466 255-261
• 24 Mariani JJ, Levin FR. Pharmacotherapy for alcohol-related disorders: what clinicians should know.  Harv Rev Psychiatry. 2004;  12 351-366
• 25 Mayo-Smith MF, Beecher LH, Fischer TL. et al . Management of alcohol withdrawal delirium. An evidence-based practice guideline.  Arch Intern Med. 2004;  164 1405-1412
• 26 Mazza M, Martini A, Scoppetta M. et al . Effect of levetiracetam on depression and anxiety in adult epileptic patients.  Prog Neuropsychopharmacol Biol Psychiatry. 2008;  32 539-543
• 27 Mula M, Sander JW. Suicidal ideation in epilepsy and levetiracetam therapy.  Epilepsy Behav. 2007;  11 130-132
• 28 Mundle G, Brugel R, Urbaniak H. et al . Short- and medium-term outcome of outpatient treatment of alcohol dependent patients. A 6-, 18- and 36-month follow-up.  Fortschr Neurol Psychiatr. 2001;  69 374-378
• 29 Noyer M, Gillard M, Matagne A. et al . The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes.  Eur J Pharmacol. 1995;  286 137-146
• 30 Patsalos PN. Pharmacokinetic profile of levetiracetam: toward ideal characteristics.  Pharmacol Ther. 2000;  85 77-85
• 31 Patsalos PN. Clinical pharmacokinetics of levetiracetam.  Clin Pharmacokinet. 2004;  43 707-724
• 32 Paul F, Meencke HJ. Levetiracetam in focal epilepsy and hepatic porphyria: a case report.  Epilepsia. 2004;  45 559-560
• 33 Peppers MP. Benzodiazepines for alcohol withdrawal in the elderly and in patients with liver disease.  Pharmacotherapy. 1996;  16 49-57
• 34 Soyka M, Morhart-Klute V, Horak M. A combination of carbamazepine/tiapride in outpatient alcohol detoxification. Results from an open clinical study.  Eur Arch Psychiatry Clin Neurosci. 2002;  252 197-200
• 35 Soyka M, Schmidt F, Schmidt P. Efficacy and safety of outpatient alcohol detoxification with a combination of tiapride/carbamazepine: additional evidence.  Pharmacopsychiatry. 2006;  39 30-34
• 36 Soyka M, Schmidt P. Outpatient alcoholism treatment – 24-month outcome and predictors of outcome.  Subst Abuse Treat Prev Policy. 2009;  4 15
• 37 Stahl SM. Psychopharmacology of anticonvulsants: levetiracetam as a synaptic vesicle protein modulator.  J Clin Psychiatry. 2004;  65 1162-1163
• 38 Webb M, Unwin A. The outcome of outpatient withdrawal from alcohol.  Br J Addict. 1988;  83 929-934
• 39 Wetterling T, Kanitz RD, Besters B. et al . A new rating scale for the assessment of the alcohol-withdrawal syndrome (AWS scale).  Alcohol Alcohol. 1997;  32 753-760
• 40 WHO . Internationale Klassifikation psychischer Störungen ICD-10 Kapitel V (F) Forschungskriterien.  Dilling H, Mombour W, Schmidt MH, Schulte-Warkwort E, eds. Huber, Bern 1994; 
• 41 Wiseman EJ, Henderson KL, Briggs MJ. Individualized treatment for outpatients withdrawing from alcohol.  J Clin Psychiatry. 1998;  59 289-293
• 42 Wittchen HU, Jacobi F. Size and burden of mental disorders in Europe – a critical review and appraisal of 27 studies.  Eur Neuropsychopharmacol. 2005;  15 357-376

Correspondence